Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells

Cancer Letters

Volumn 341, Issue 1, 2013, Pages 41-45

  Espinoza, Ingrid ^a   Miele, Lucio ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; EMT; EndMT; Notch inhibitors; Notch signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXEMESTANE; GAMMA SECRETASE INHIBITOR; GEFITINIB; GEMCITABINE; GLUCOCORTICOID; LETROZOLE; MK 0752; MONOCLONAL ANTIBODY; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH INHIBITOR; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PROTEIN INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE;

BREAST CANCER; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL FATE; CELL RENEWAL; DIARRHEA; DRUG POTENTIATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VASCULARIZATION;

EID: 84887154867     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.027     Document Type: Review

References (56)

1. Thiery J.P. Epithelial-mesenchymal transitions in cancer onset and progression. Bulletin de l'Academie nationale de medecine 2009, 193:1969-1978. (discussion 1978-1969).
2. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
3. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
4. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
5. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research 2009, 69:2400-2407.
6. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
7. Xie M., Zhang L., He C.S., Xu F., Liu J.L., Hu Z.H., Zhao L.P., Tian Y. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. Journal of Cellular Biochemistry 2012, 113:1501-1513.
8. Espinoza I., Miele L. Notch inhibitors for cancer treatment. Pharmacology & Therapeutics 2013.
9. Potenta S., Zeisberg E., Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. British Journal of Cancer 2008, 99:1375-1379.
10. Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997, 90:281-291.
11. Dunwoodie S.L., Henrique D., Harrison S.M., Beddington R.S. Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 1997, 124:3065-3076.
12. Lindsell C.E., Shawber C.J., Boulter J., Weinmaster G. Jagged: a mammalian ligand that activates Notch1. Cell 1995, 80:909-917.
13. Shawber C., Boulter J., Lindsell C.E., Weinmaster G. Jagged2: a serrate-like gene expressed during rat embryogenesis. Developmental Biology 1996, 180:370-376.
14. Brou C., Logeat F., Gupta N., Bessia C., LeBail O., Doedens J.R., Cumano A., Roux P., Black R.A., Israel A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Molecular Cell 2000, 5:207-216.
15. Saxena M.T., Schroeter E.H., Mumm J.S., Kopan R. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. The Journal of Biological Chemistry 2001, 276:40268-40273.
16. Hsieh J.J., Zhou S., Chen L., Young D.B., Hayward S.D. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:23-28.
17. Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S., Griffin J.D. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nature Genetics 2000, 26:484-489.
18. Maier M.M., Gessler M. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochemical and Biophysical Research Communications 2000, 275:652-660.
19. Ronchini C., Capobianco A.J. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Molecular and Cellular Biology 2001, 21:5925-5934.
20. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., Del Bianco C., Rodriguez C.G., Sai H., Tobias J., Li Y., Wolfe M.S., Shachaf C., Felsher D., Blacklow S.C., Pear W.S., Aster J.C. C-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes & Development 2006, 20:2096-2109.
21. Wang Z., Li Y., Kong D., Sarkar F.H. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Current Drug Targets 2010, 11:745-751.
22. Becker K.F., Rosivatz E., Blechschmidt K., Kremmer E., Sarbia M., Hofler H. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells, Tissues, Organs 2007, 185:204-212.
23. Sahlgren C., Gustafsson M.V., Jin S., Poellinger L., Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:6392-6397.
24. Niessen K., Fu Y., Chang L., Hoodless P.A., McFadden D., Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. The Journal of Cell Biology 2008, 182:315-325.
25. Leong K.G., Niessen K., Kulic I., Raouf A., Eaves C., Pollet I., Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. The Journal of Experimental Medicine 2007, 204:2935-2948.
26. Niimi H., Pardali K., Vanlandewijck M., Heldin C.H., Moustakas A. Notch signaling is necessary for epithelial growth arrest by TGF-beta. The Journal of Cell Biology 2007, 176:695-707.
27. Zavadil J., Cermak L., Soto-Nieves N., Bottinger E.P. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. The EMBO Journal 2004, 23:1155-1165.
28. Kong D., Banerjee S., Ahmad A., Li Y., Wang Z., Sethi S., Sarkar F.H. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PloS One 2010, 5:e12445.
29. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48:37-43.
30. Papachristou D.J., Basdra E.K., Papavassiliou A.G. Bone metastases: molecular mechanisms and novel therapeutic interventions. Medicinal Research Reviews 2012, 32:611-636.
31. Sethi S., Macoska J., Chen W., Sarkar F.H. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. American Journal of Translational Research 2010, 3:90-99.
32. Zhu H., Zhou X., Redfield S., Lewin J., Miele L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. American Journal of Translational Research 2013, 5:368-378.
33. Gustafsson M.V., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., Ruas J.L., Poellinger L., Lendahl U., Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Developmental Cell 2005, 9:617-628.
34. Zheng X., Linke S., Dias J.M., Gradin K., Wallis T.P., Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L., Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J., Peet D.J., Lendahl U., Poellinger L. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:3368-3373.
35. Main H., Lee K.L., Yang H., Haapa-Paananen S., Edgren H., Jin S., Sahlgren C., Kallioniemi O., Poellinger L., Lim B., Lendahl U. Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. Experimental Cell Research 2010, 316:1610-1624.
36. Gu J.W., Rizzo P., Pannuti A., Golde T., Osborne B., Miele L. Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy. Vascular Cell 2012, 4:7.
37. Xing F., Okuda H., Watabe M., Kobayashi A., Pai S.K., Liu W., Pandey P.R., Fukuda K., Hirota S., Sugai T., Wakabayshi G., Koeda K., Kashiwaba M., Suzuki K., Chiba T., Endo M., Mo Y.Y., Watabe K. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 2011, 30:4075-4086.
38. Brabletz S., Bajdak K., Meidhof S., Burk U., Niedermann G., Firat E., Wellner U., Dimmler A., Faller G., Schubert J., Brabletz T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. The EMBO Journal 2011, 30:770-782.
39. Yang Y., Ahn Y.H., Gibbons D.L., Zang Y., Lin W., Thilaganathan N., Alvarez C.A., Moreira D.C., Creighton C.J., Gregory P.A., Goodall G.J., Kurie J.M. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. The Journal of Clinical Investigation 2011, 121:1373-1385.
40. Sabbah M., Emami S., Redeuilh G., Julien S., Prevost G., Zimber A., Ouelaa R., Bracke M., De Wever O., Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resistance Updates 2008, 11:123-151.
41. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., Banerjee S., Azmi A.S., Miele L., Sarkar F.H. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Letters 2011, 307:26-36.
42. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. International Journal of Oncology 2007, 31:277-283.
43. Sayan A.E., Griffiths T.R., Pal R., Browne G.J., Ruddick A., Yagci T., Edwards R., Mayer N.J., Qazi H., Goyal S., Fernandez S., Straatman K., Jones G.D., Bowman K.J., Colquhoun A., Mellon J.K., Kriajevska M., Tulchinsky E. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:14884-14889.
44. Iseri O.D., Kars M.D., Arpaci F., Atalay C., Pak I., Gunduz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomedicine & Pharmacotherapy 2011, 65:40-45.
45. Gungor C., Zander H., Effenberger K.E., Vashist Y.K., Kalinina T., Izbicki J.R., Yekebas E., Bockhorn M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Research 2011, 71:5009-5019.
46. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., Lockwood G., Egan S.E. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research 2005, 65:8530-8537.
47. Luistro L., He W., Smith M., Packman K., Vilenchik M., Carvajal D., Roberts J., Cai J., Berkofsky-Fessler W., Hilton H., Linn M., Flohr A., Jakob-Rotne R., Jacobsen H., Glenn K., Heimbrook D., Boylan J.F. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Research 2009, 69:7672-7680.
48. Rao S.S., O'Neil J., Liberator C.D., Hardwick J.S., Dai X., Zhang T., Tyminski E., Yuan J., Kohl N.E., Richon V.M., Van der Ploeg L.H., Carroll P.M., Draetta G.F., Look A.T., Strack P.R., Winter C.G. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Research 2009, 69:3060-3068.
49. Pandya K., Meeke K., Clementz A.G., Rogowski A., Roberts J., Miele L., Albain K.S., Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer 2011, 105:796-806.
50. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J., Clarke R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Research 2010, 70:709-718.
51. Samon J.B., Castillo-Martin M., Hadler M., Ambesi-Impiobato A., Paietta E., Racevskis J., Wiernik P.H., Rowe J.M., Jakubczak J., Randolph S., Cordon-Cardo C., Ferrando A.A. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Molecular Cancer Therapeutics 2012, 11:1565-1575.
52. Rizzo P., Miao H., D'Souza G., Osipo C., Song L.L., Yun J., Zhao H., Mascarenhas J., Wyatt D., Antico G., Hao L., Yao K., Rajan P., Hicks C., Siziopikou K., Selvaggi S., Bashir A., Bhandari D., Marchese A., Lendahl U., Qin J.Z., Tonetti D.A., Albain K., Nickoloff B.J., Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research 2008, 68:5226-5235.
53. Albain K., Czerlanis C., Zlobin A., Covington K.R., Rajan P., Godellas C., et al. Modulation of cancer stem cell biomarkers by the notch inhibitor MK0752 added to endocrine therapy for early stage ER+ breast cancer. Cancer Research 2011, 71:97s.
54. Means-Powell J.A., Mayer I.A., Abramson V.G., Ismail-Khan R., Arteaga C.L., Ayers D.A., Sanders M.S., Lush R.M., Miele L. A phase Ib dose escalation trial of RO4929097 (a γ-secretase inhibitor) in combination with exemestane in patients with ER+ metastatic breast cancer. Cancer Research 2012, 72:280s.
55. Jieun Yun A.P., Espinoza Ingrid, Zhu He, Hicks Chindo, Zhu Xiaomei, Caskey Mary, Rizzo Paola, D'Souza Gwendolyn, Backus Kandis, Denning Mitchell F., Coon John, Sun Miao, Bresnick Emery H., Osipo Clodia, Wu Jing, Strack Peter R., Tonett5 Debra A., Tonett5 Debra A., Miele Lucio Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis 2013.
56. Schott A.F., Landis M.D., Dontu G., Griffith K.A., Layman R.M., Krop I., Paskett L.A., Wong H., Dobrolecki L.E., Lewis M.T., Froehlich A.M., Paranilam J., Hayes D.F., Wicha M.S., Chang J.C. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2013, 19:1512-1524.